{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:59:38Z","timestamp":1753437578390,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Primary bilateral adrenal hyperplasia (PBMAH) is associated with hypercortisolism and a heterogeneous clinical expression in terms of cortisol secretion and related comorbidities. Historically, treatment of choice was bilateral adrenalectomy (B-Adx); however, recent data suggest that unilateral adrenalectomy (U-Adx) may be an effective alternative. For the latter, factors predicting the postsurgical outcome (e.g., biochemical control) have not been identified yet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PBMAH patients undergoing U-Adx for overt Cushing\u2019s syndrome (CS) in two tertiary care centers were retrospectively analysed. Remission was defined as a normalization of urinary free cortisol (UFC) without the need for medical treatment. The potential of hCRH test as a predictor of U-Adx outcome was evaluated in a subgroup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>23 patients were evaluated (69% females, mean age 55\u00a0years). Remission rate after U-Adx was 74% at last follow up (median 115\u00a0months from UAdx). Before U-Adx, a positive ACTH response to hCRH (\u0394%ACTH increase\u2009&gt;\u200950% from baseline) was associated with higher remission rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Three of four patients with PBMAH are surgically cured with U-Adx. Pre-operative hCRH testing can be useful to predict long-term remission rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02204-2","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:02:08Z","timestamp":1696500128000},"page":"749-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Corticotropin-releasing hormone test predicts the outcome of unilateral adrenalectomy in primary bilateral macronodular adrenal hyperplasia"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4092-5107","authenticated-orcid":false,"given":"I.","family":"Tizianel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-5575","authenticated-orcid":false,"given":"M.","family":"Detomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-0168","authenticated-orcid":false,"given":"T.","family":"Deutschbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"M.","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-4362","authenticated-orcid":false,"given":"N.","family":"Albiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-4642","authenticated-orcid":false,"given":"M.","family":"Iacobone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3815","authenticated-orcid":false,"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"F.","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"2204_CR1","doi-asserted-by":"publisher","first-page":"b117","DOI":"10.1159\/000134829","volume-title":"Disorders of the human adrenal cortex","author":"CA Stratakis","year":"2008","unstructured":"Stratakis CA (2008) Cushing syndrome caused by adrenocortical tumors and hyperplasias (Corticotropin-independent cushing syndrome). In: Fl\u00fcck CE, Miller WL (eds) Disorders of the human adrenal cortex. KARGER, Basel, pp b117-132"},{"issue":"3","key":"2204_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12020-021-02645-w","volume":"71","author":"L Bouys","year":"2021","unstructured":"Bouys L, Chiodini I, Arlt W, Reincke M, Bertherat J (2021) Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). Endocrine 71(3):595\u2013603. https:\/\/doi.org\/10.1007\/s12020-021-02645-w","journal-title":"Endocrine"},{"issue":"8 SUPPL.","key":"2204_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3275\/7349","volume":"34","author":"NM Albiger","year":"2011","unstructured":"Albiger NM, Occhi G, Sanguin F et al (2011) Adrenal nodules in patients with Cushing\u2019s disease: prevalence, clinical significance and follow-up. J Endocrinol Invest 34(8 SUPPL.):1\u201320. https:\/\/doi.org\/10.3275\/7349","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2204_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/EJE-10-0962","volume":"164","author":"F Pecori Giraldi","year":"2011","unstructured":"Pecori Giraldi F, Saccani A, Cavagnini F (2011) Assessment of ACTH assay variability: a multicenter study. Eur J Endocrinol 164(4):505\u2013512. https:\/\/doi.org\/10.1530\/EJE-10-0962","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2204_CR5","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1210\/jc.2009-0612","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Arnaldi G (2009) Approach to the patient with possible cushing\u2019s syndrome. J Clin Endocrinol Metab 94(9):3121\u20133131. https:\/\/doi.org\/10.1210\/jc.2009-0612","journal-title":"J Clin Endocrinol Metab"},{"issue":"9996","key":"2204_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet (London, England) 386(9996):913\u2013927. https:\/\/doi.org\/10.1016\/S0140-6736(14)61375-1","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2204_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.beem.2008.10.011","volume":"23","author":"A Lacroix","year":"2009","unstructured":"Lacroix A (2009) ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23(2):245\u2013259. https:\/\/doi.org\/10.1016\/j.beem.2008.10.011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"852","key":"2204_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/pgmj.72.852.614","volume":"72","author":"M Boronat","year":"1996","unstructured":"Boronat M, Lucas T, Barcel\u00f3 B, Alameda C, Hotait H, Estrada J (1996) Cushing\u2019s syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy. Postgrad Med J 72(852):614\u2013616. https:\/\/doi.org\/10.1136\/pgmj.72.852.614","journal-title":"Postgrad Med J"},{"issue":"2","key":"2204_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101486","volume":"35","author":"L Meloche-Dumas","year":"2021","unstructured":"Meloche-Dumas L, Mercier F, Lacroix A (2021) Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(2):101486. https:\/\/doi.org\/10.1016\/j.beem.2021.101486","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2204_CR10","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1210\/jc.2015-2662","volume":"100","author":"E Debillon","year":"2015","unstructured":"Debillon E, Velayoudom-Cephise F-L, Salenave S et al (2015) Unilateral adrenalectomy as a first-line treatment of cushing\u2019s syndrome in patients with primary bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 100(12):4417\u20134424. https:\/\/doi.org\/10.1210\/jc.2015-2662","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2204_CR11","doi-asserted-by":"publisher","first-page":"E1501","DOI":"10.1210\/jc.2013-4237","volume":"99","author":"GA Alencar","year":"2014","unstructured":"Alencar GA, Lerario AM, Nishi MY et al (2014) ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. J Clin Endocrinol Metab 99(8):E1501\u2013E1509. https:\/\/doi.org\/10.1210\/jc.2013-4237","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2204_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(21)00236-9","volume":"9","author":"F Chasseloup","year":"2021","unstructured":"Chasseloup F, Bourdeau I, Tabarin A et al (2021) Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing\u2019s syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol 9(12):813\u2013824. https:\/\/doi.org\/10.1016\/S2213-8587(21)00236-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2204_CR13","doi-asserted-by":"publisher","first-page":"E1784","DOI":"10.1210\/jc.2014-1265","volume":"99","author":"L Gagliardi","year":"2014","unstructured":"Gagliardi L, Schreiber AW, Hahn CN et al (2014) ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 99(9):E1784\u2013E1792. https:\/\/doi.org\/10.1210\/jc.2014-1265","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2204_CR14","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1056\/NEJMoa1304603","volume":"369","author":"G Assi\u00e9","year":"2013","unstructured":"Assi\u00e9 G, Lib\u00e9 R, Espiard S et al (2013) ARMC5 mutations in macronodular adrenal hyperplasia with cushing\u2019s syndrome. N Engl J Med 369(22):2105\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa1304603","journal-title":"N Engl J Med"},{"issue":"3","key":"2204_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12020-016-0956-z","volume":"55","author":"NM Albiger","year":"2017","unstructured":"Albiger NM, Regazzo D, Rubin B et al (2017) A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine 55(3):959\u2013968. https:\/\/doi.org\/10.1007\/s12020-016-0956-z","journal-title":"Endocrine"},{"issue":"6","key":"2204_CR16","doi-asserted-by":"publisher","first-page":"E926","DOI":"10.1210\/jc.2014-4204","volume":"100","author":"S Espiard","year":"2015","unstructured":"Espiard S, Drougat L, Lib\u00e9 R et al (2015) ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. J Clin Endocrinol Metab 100(6):E926\u2013E935. https:\/\/doi.org\/10.1210\/jc.2014-4204","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2204_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/cen.12763","volume":"82","author":"NM Albiger","year":"2015","unstructured":"Albiger NM, Ceccato F, Zilio M et al (2015) An analysis of different therapeutic options in patients with Cushing\u2019s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin Endocrinol (Oxf) 82(6):808. https:\/\/doi.org\/10.1111\/cen.12763","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2204_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac034","author":"J Bertherat","year":"2022","unstructured":"Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenick\u00fd P, Lacroix A (2022) Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnac034","journal-title":"Endocr Rev"},{"issue":"7","key":"2204_CR19","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1210\/jc.2018-02204","volume":"104","author":"A Osswald","year":"2019","unstructured":"Osswald A, Quinkler M, Di Dalmazi G et al (2019) Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy. J Clin Endocrinol Metab 104(7):2985\u20132993. https:\/\/doi.org\/10.1210\/jc.2018-02204","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2204_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1530\/EJE-10-0195","volume":"163","author":"R Lib\u00e9","year":"2010","unstructured":"Lib\u00e9 R, Coste J, Guignat L et al (2010) Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing\u2019s syndrome. Eur J Endocrinol 163(1):129\u2013138. https:\/\/doi.org\/10.1530\/EJE-10-0195","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2204_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1750-1172-8-142","volume":"8","author":"J Hofland","year":"2013","unstructured":"Hofland J, Hofland LJ, Van Koetsveld PM et al (2013) ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11\u03b2-hydroxylase. Orphanet J Rare Dis 8(1):142. https:\/\/doi.org\/10.1186\/1750-1172-8-142","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2204_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eprac.2022.04.011","volume":"28","author":"W Wang","year":"2022","unstructured":"Wang W, Lian P, Deng J, Li H, Zhang X (2022) A 30-year, single-center experience of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia. Endocr Pract 28(7):690\u2013695. https:\/\/doi.org\/10.1016\/j.eprac.2022.04.011","journal-title":"Endocr Pract"},{"key":"2204_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa083","author":"F Yoshiaki Tanno","year":"2020","unstructured":"Yoshiaki Tanno F, Srougi V, Almeida MQ et al (2020) A new insight into the surgical treatment of primary macronodular adrenal hyperplasia. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvaa083","journal-title":"J Endocr Soc"},{"issue":"12","key":"2204_CR24","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi G, Angeli A, Atkinson AB et al (2003) Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 88(12):5593. https:\/\/doi.org\/10.1210\/jc.2003-030871","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2204_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11102-022-01222-2","volume":"25","author":"C Scaroni","year":"2022","unstructured":"Scaroni C, Mondin A, Ceccato F (2022) How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing). Pituitary 25(5):701\u2013704. https:\/\/doi.org\/10.1007\/s11102-022-01222-2","journal-title":"Pituitary"},{"issue":"2","key":"2204_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00024677-200201020-00002","volume":"1","author":"C Beauregard","year":"2002","unstructured":"Beauregard C, Dickstein G, Lacroix A (2002) Classic and recent etiologies of Cushing\u2019s syndrome: diagnosis and therapy. Treat Endocrinol 1(2):79\u201394. https:\/\/doi.org\/10.2165\/00024677-200201020-00002","journal-title":"Treat Endocrinol"},{"issue":"1","key":"2204_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1530\/EJE-10-0195","volume":"163","author":"R Lib\u00e9","year":"2010","unstructured":"Lib\u00e9 R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B, Bertagna X, Bertherat J, Groussin L (2010) Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing\u2019s syndrome. Eur J Endocrinol 163(1):129\u2013138. https:\/\/doi.org\/10.1530\/EJE-10-0195","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2204_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11102-016-0729-y","volume":"19","author":"M Barbot","year":"2016","unstructured":"Barbot M, Trementino L, Zilio M et al (2016) Second-line tests in the differential diagnosis of ACTH-dependent Cushing\u2019s syndrome. Pituitary 19(5):488\u2013495. https:\/\/doi.org\/10.1007\/s11102-016-0729-y","journal-title":"Pituitary"},{"key":"2204_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.955945","author":"M Detomas","year":"2022","unstructured":"Detomas M, Ritzel K, Nasi-Kordhishti I et al (2022) Outcome of CRH stimulation test and overnight 8 mg dexamethasone suppression test in 469 patients with ACTH-dependent Cushing\u2019s syndrome. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.955945","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2204_CR30","doi-asserted-by":"publisher","first-page":"e3938","DOI":"10.1210\/clinem\/dgaa564","volume":"105","author":"F Ceccato","year":"2020","unstructured":"Ceccato F, Tizianel I, Vedolin CK, Boscaro M, Barbot M, Scaroni C (2020) Human corticotropin-releasing hormone tests: 10 years of real-life experience in pituitary and adrenal disease. J Clin Endocrinol Metab 105(11):e3938\u2013e3949. https:\/\/doi.org\/10.1210\/clinem\/dgaa564","journal-title":"J Clin Endocrinol Metab"},{"key":"2204_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02113-4","author":"F Ceccato","year":"2023","unstructured":"Ceccato F, Di Dalmazi G (2023) Shortage of hCRH for the diagnosis of endogenous CS: the end of an era or the beginning of a new journey? J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02113-4","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02204-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:31:02Z","timestamp":1709227862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02204-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2204"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02204-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest for this topic that might be perceived as influencing the impartiality of the reported research. Filippo Ceccato: PhD grant by Novartis Pharma, Lecture fees by HRA Pharma. Timo Deutschbein: personal honorary for Advisory Boards (HRA Pharma, Recordati Rare Diseases).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Comitato Etico per la Sperimentazione Clinica, Prot. 0042129 of 2023) and with the Helsinki Declaration Of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}